Subscribe to stay informed!
Exton-based biopharmaceutical company Immunome has completed a reverse merger with a Seattle-based company dedicated to making strides in cancer therapies, writes John George…
Exton-based Immunome has reported positive results from testing its antibody cocktail against live versions of the omicron variant of COVID-19. John George broke…
Despite the disruptions caused by the coronavirus pandemic and labor shortages, Philadelphia experienced a venture capital boom in 2021, write Taylor Allen and Mike D…
Exton-based Immunome has submitted an application with the FDA to start human testing its “antibody cocktail” as a potential COVID-19 treatment, writes John…
Exton-based Immunome is developing an “antibody cocktail” to fight COVID-19 variants of concern. The World Health Organization and Center for Disease Control classified…
Exton-based Immunome has entered into a deal with a group of accredited investors to raise $27 million through a private stock placement, writes John…
Immunome saw its stock soar after the Exton-based company discovered antibodies that have shown, in early testing, the ability to neutralize multiple variants of…
Local commercial real estate markets are thriving as a number of Philadelphia startups search out more affordable space in the suburbs due to the coronavirus…
Immunome, an Exton-based biopharmaceutical company, went public last week and managed to raise $39 million through an upsized initial public stock offering, writes John…
Before we send you to this site, please subscribe to our daily newsletter.